Literature DB >> 12407026

IL-22, in contrast to IL-10, does not induce Ig production, due to absence of a functional IL-22 receptor on activated human B cells.

Sandrine Lécart1, Frank Morel, Nelly Noraz, Jérôme Pène, Martine Garcia, Katia Boniface, Jean-Claude Lecron, Hans Yssel.   

Abstract

IL-22 is an IL-10 homologue that binds to and signals via the class II cytokine receptor (R) heterodimer IL-22RA1/CFR2-4 (IL-10R2), the latter chain being part of the IL-10R complex. Here, we report that, despite its structural similarity with IL-10, as well as its use of the common IL-10R2 chain, IL-22, in contrast to IL-10, is unable to induce Ig production by activated human B cells. Whereas culture of anti-CD40 mAb-stimulated splenic or tonsillar B cells in the presence of rIL-10 resulted in the production of IgG, IgG1, IgG3 and IgA, rIL-22, at concentrations ranging from 4 to 100 ng/ml, did not induce the production of any of these isotypes. Moreover, unlike rIL-10 which enhanced rIL-4-induced IgG4 and IgE production, rIL-22 was ineffective. Although activated B cells expressed transcripts for a soluble IL-22-binding protein (IL-22RA2), no mRNA for a transmembrane IL-22R (IL-22RA1) could be detected. The latter result was confirmed by the demonstration that rIL-22 failed to induce activation of STAT-3 and -5 in resting or activated B cells. Together, these data show that IL-22, in contrast to its homologue IL-10, is not involved in the immunological activity of B cells, which is due to the absence of a functional IL-22R at the surface of these cells.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12407026     DOI: 10.1093/intimm/dxf096

Source DB:  PubMed          Journal:  Int Immunol        ISSN: 0953-8178            Impact factor:   4.823


  14 in total

1.  Interleukin 22 signaling promotes cell growth in mantle cell lymphoma.

Authors:  Pascal Gelebart; Zoulika Zak; Jennifer Dien-Bard; Mona Anand; Raymond Lai
Journal:  Transl Oncol       Date:  2011-02-01       Impact factor: 4.243

2.  Prototypical anti-inflammatory cytokine IL-10 prevents loss of IGF-I-induced myogenin protein expression caused by IL-1beta.

Authors:  Klemen Strle; Robert H McCusker; Rodney W Johnson; Samantha M Zunich; Robert Dantzer; Keith W Kelley
Journal:  Am J Physiol Endocrinol Metab       Date:  2008-02-12       Impact factor: 4.310

3.  Therapeutic Role of Interleukin 22 in Experimental Intra-abdominal Klebsiella pneumoniae Infection in Mice.

Authors:  Mingquan Zheng; William Horne; Jeremy P McAleer; Derek Pociask; Taylor Eddens; Misty Good; Bin Gao; Jay K Kolls
Journal:  Infect Immun       Date:  2016-01-04       Impact factor: 3.441

Review 4.  Interleukin-22: immunobiology and pathology.

Authors:  Jarrod A Dudakov; Alan M Hanash; Marcel R M van den Brink
Journal:  Annu Rev Immunol       Date:  2015-02-11       Impact factor: 28.527

Review 5.  The biological functions of T helper 17 cell effector cytokines in inflammation.

Authors:  Wenjun Ouyang; Jay K Kolls; Yan Zheng
Journal:  Immunity       Date:  2008-04       Impact factor: 31.745

6.  Interleukin-22 suppresses the growth of A498 renal cell carcinoma cells via regulation of STAT1 pathway.

Authors:  Fengbo Zhang; Donghao Shang; Yuhai Zhang; Ye Tian
Journal:  PLoS One       Date:  2011-05-23       Impact factor: 3.240

7.  Interleukin (IL)-21 promotes intestinal IgA response to microbiota.

Authors:  A T Cao; S Yao; B Gong; R I Nurieva; C O Elson; Y Cong
Journal:  Mucosal Immunol       Date:  2015-01-14       Impact factor: 7.313

8.  Endogenous IL-22 plays a dual role in arthritis: regulation of established arthritis via IFN-γ responses.

Authors:  Shivali Justa; Xiaoqun Zhou; Sujata Sarkar
Journal:  PLoS One       Date:  2014-03-27       Impact factor: 3.240

9.  Immune modulatory effects of IL-22 on allergen-induced pulmonary inflammation.

Authors:  Ping Fang; Li Zhou; Yuqi Zhou; Jay K Kolls; Tao Zheng; Zhou Zhu
Journal:  PLoS One       Date:  2014-09-25       Impact factor: 3.240

10.  Rheumatoid synovial fluid interleukin-17-producing CD4 T cells have abundant tumor necrosis factor-alpha co-expression, but little interleukin-22 and interleukin-23R expression.

Authors:  Leigh D Church; Andrew D Filer; Esther Hidalgo; Katherine A Howlett; Andrew M C Thomas; Stephen Rapecki; Dagmar Scheel-Toellner; Christopher D Buckley; Karim Raza
Journal:  Arthritis Res Ther       Date:  2010-10-07       Impact factor: 5.156

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.